GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » EV-to-FCF

Celcuity (Celcuity) EV-to-FCF : -5.99 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Celcuity EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Celcuity's Enterprise Value is $348.71 Mil. Celcuity's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-58.19 Mil. Therefore, Celcuity's EV-to-FCF for today is -5.99.

The historical rank and industry rank for Celcuity's EV-to-FCF or its related term are showing as below:

CELC' s EV-to-FCF Range Over the Past 10 Years
Min: -18.66   Med: 0   Max: 0
Current: -5.99

CELC's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs CELC: -5.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Celcuity's stock price is $15.64. Celcuity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.770. Therefore, Celcuity's PE Ratio for today is At Loss.


Celcuity EV-to-FCF Historical Data

The historical data trend for Celcuity's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity EV-to-FCF Chart

Celcuity Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -14.21 -11.47 -6.25 -4.71 -4.24

Celcuity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 -3.20 -2.39 -4.24 -9.02

Competitive Comparison of Celcuity's EV-to-FCF

For the Biotechnology subindustry, Celcuity's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celcuity's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Celcuity's EV-to-FCF falls into.



Celcuity EV-to-FCF Calculation

Celcuity's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=348.707/-58.193
=-5.99

Celcuity's current Enterprise Value is $348.71 Mil.
Celcuity's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celcuity  (NAS:CELC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Celcuity's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15.64/-2.770
=At Loss

Celcuity's share price for today is $15.64.
Celcuity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.770.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Celcuity EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Celcuity's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Celcuity (Celcuity) Business Description

Traded in Other Exchanges
N/A
Address
16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
Executives
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey director C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht director C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan director, 10 percent owner, officer: Chief Executive Officer 16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing director, 10 percent owner, officer: Chief Science Officer, VP C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne officer: Chief Financial Officer C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin director C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446